Meyka Pro banner
Neumora Therapeutics, Inc. Common Stock

Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) AI-Powered Stock Analysis

See how Neumora Therapeutics, Inc. Common Stock scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

NMRANASDAQ
HealthcareBiotechnology
$1.66
$0.17(11.41%)
U.S. Market opens in 14h 24m

Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) AI-Powered Stock Analysis

See how Neumora Therapeutics, Inc. Common Stock scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.

Model Information

The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimer

Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) Stock Overall Grade

Neumora Therapeutics, Inc. Common Stock's grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.

Z

Grade Breakdown by Metric

See how each financial and market factor contributes to Neumora Therapeutics, Inc. Common Stock's overall NASDAQ stock rating.

Forecast

C+

Score

55/100

Financial Growth

C

Score

40/100

Fundamental Growth

C+

Score

51/100

Key Ratios

C+

Score

55/100

Sector Comparison

B

Score

65/100

Industry Comparison

C+

Score

50/100

S&P 500 Benchmark

A+

Score

97/100

Analyst Consensus

B+

Score

75/100

Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) AI-Powered Stock Analysis

On the NASDAQ, NMRA demonstrates Good performance with an overall Forecast Score of 55/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (51/100, C+) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (65/100, B) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (97/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (75/100, B+) suggests Moderate divergence in outlook.

(NASDAQ: NMRA) Component Analysis Explained

Understand the key factors behind each Neumora Therapeutics, Inc. Common Stock (NASDAQ: NMRA) stock grade, including financials, comparisons, and forecasts.

Frequently Asked Questions